What can modeling tell us about the threat of antiviral drug resistance?

Current Opinion in Infectious Diseases

Volumn 15, Issue 6, 2002, Pages 609-614

  Blower, Sally ^a   Volberding, Paul ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiviral; Drug resistance; Mathematical model

Indexed keywords

ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; ZIDOVUDINE;

COST BENEFIT ANALYSIS; EPIDEMIC; HEALTH CARE POLICY; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; INFLUENZA VIRUS; MATHEMATICAL MODEL; MULTIDRUG RESISTANCE; NONHUMAN; PREVALENCE; REVIEW; VIRUS INFECTION; VIRUS RESISTANCE;

EID: 0036910787     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-200212000-00009     Document Type: Review

References (33)

1. Bernoulli D. An attempt at a new analysis of the mortality caused by smallpox and of the advantages of inoculation to prevent it [in French]. Mem Math Phys Acad Roy Soc Paris 1760; 1-45.
2. Anderson RM, Gupta S, May RM. Potential of community-wide chemotherapy or immunotherapy to control the spread of HIV-1. Nature 1991; 350:356-359.
3. Paltiel AD, Kaplan EH. Modeling zidovudine therapy: A cost-effectiveness analysis. J Acquir Immune Defic Syndr 1991; 4:795-804.
4. Gupta S, May RM, Anderson RM. Mathematical models and the design of public health policy: HIV and antiviral therapy. Soc Ind Appl Math Rev 1993; 35:1-16.
5. Velasco-Hernandez JX, Hsieh YH. Modeling the effect of treatment and behavioral change in HIV transmission dynamics. J Math Biol 1994; 32:233-249.
6. Hsieh YH, Velasco-Hernandez JX. Community treatment of HIV-1: Initial stage and asymptotic dynamics. Biosystems 1995; 35:75-81.
7. Velasco-Hernández JX, Brauer F, Castillo-Chavez C. Effects of treatment and prevalence-dependent recruitment on the dynamics of a fatal disease. IMA J Math Appl Med Biol 1996; 13:175-192.
8. Blower SM, Gershengorn H, Grant RM. A tale of two futures: HIV and antiretroviral therapy in San Francisco. Science 2000; 287:650-654.
9. Blower SM, Aschenbach AN, Gershengorn H, Kahn JO. Predicting the unpredictable: Transmission of drug-resistant HIV. Nat Med 2001; 7:1016-1020. The first analysis to predict levels of transmitted resistance. The authors use time-dependent uncertainty analysis to make predictions from 1996 to 2005.
10. Velasco-Hernandez JX, Gershengorn HB, Blower SM. Could widespread usage of combination antiretroviral therapy eradicate HIV epidemics? The Lancet Infect Dis 2002; 2:487-493. The first analysis to show that a high usage of antiretroviral therapies could lead to the eradication of even a high-prevalence (30%) HIV epidemic (even if high levels of drug resistance arise).
11. Tchetgen E, Kaplan EH, Friedland GH. Public health consequences of screening patients for adherence to highly active antiretroviral therapy. JAIDS 2001; 26:118-129. The first analysis to evaluate the effect of screening for adherence on the incidence of HIV, AIDS and the emergence of drug resistance.
12. Law MG, Prestage G, Grulich A, et al. Modelling the effect of combination antiretroviral treatments on HIV incidence. AIDS 2001; 15:1287-1294. Evaluates the epidemiological trade-off between decreases in transmission due to ART and increases in transmission due to increases in risky sex in the gay community in Australia.
13. Goudsmit J, Weveling GJ, van der Hoak L, et al. Carrier rate of zidovudine-resistant HIV-1: The impact of failing therapy on transmission of resistant strains. AIDS 2001; 15:2293-2301. Compares theory and data and evaluates the effect of changes in the usage rate of antiretroviral therapies on the transmission of zidovudine-resistant strains.
14. Blower SM, Small PM, Hopewell PC. Control strategies for tuberculosis epidemics: New models for old problems. Science 1996; 273:497-500.
15. Blower SM, Gerberding JLG. Understanding, predicting & controlling the emergence of drug-resistant tuberculosis: A theoretical framework. J Mol Med 1998; 76:624-636.
16. Blower SM, Koelle K, Lietman TC. Antibiotic resistance: To treat ... (or not to treat)? Nat Med 1999; 5:358-359.
17. Blower SM, Porco TC, Lietman TC. Tuberculosis: The evolution of antibiotic resistance and the design of epidemic control strategies. In: Horn, Simonett, Webb, editors. Mathematical Models in Medical & Health Sciences. Vanderbilt University Press; 1998.
18. Blower SM, Porco TC, Darby G. Predicting and preventing the emergence of antiviral drug resistance in HSV-2. Nat Med 1998; 4:664-665.
19. Gershengorn HB, Blower SM. The impact of antivirals and the emergence of drug resistance: HSV-2 epidemic control. AIDS Patient Care STDs 2000; 14:133-142.
20. Stilianakis NI, Perelson AS, Hayden FG. Emergence of drug resistance during an influenza epidemic: Insights from a mathematical model. J Infect Dis 1998; 177:863-873.
21. Blower SM, Gershengorn HB, Grant RM. Supplementary Data Online; 2000. Science Online www.sciencemag.org/feature/data/1044287.shl.
22. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385-394.
23. Grant RM, Hecht FM, Warmerdam M, et al. Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002; 288:181-188.
24. Blower SM, Hartel D, Dowlatabadi H, et al. Drugs, sex and HIV: A mathematical model for New York City. Phil Trans Roy Soc Series B 1991; 321:171-187.
25. Blower SM, Dowlatabadi H. Sensitivity and uncertainty analysis of complex models of disease transmission: An HIV model, as an example. Int Stat Rev 1994; 2:229-243.
26. Blower SM, McLean AR, Porco TC, et al. The intrinsic transmission dynamics of tuberculosis epidemics. Nat Med 1995; 1:815-821.
27. Sanchez MA, Blower SM. Uncertainty & sensitivity analysis of the basic reproductive rate: Tuberculosis as an example. Am J Epidemiol 1997; 145:1127-1138.
28. Iman RL, Helton JC, Campbell JE. An approach to sensitivity analysis of computer models. I: Introduction, input variable selection and preliminary variable assessment. J Qual Technol 1981; 13:174-183.
29. Iman RL, Helton JC, Campbell JE. An approach to sensitivity analysis of computer models. II: Ranking of input variables, response surface validation, distribution effect and technique synopsis. J Qual Technol 1981; 13:232-240.
30. Blower S, Koelle K, Kirschner D, Mills J. Live attenuated HIV vaccines: Predicting the trade-off between efficacy and safety. PNAS 2001; 98:3618-3623.
31. Blower SM, Koelle K, Mills J. Health policy modeling: Epidemic control, HIV vaccines & risky behavior. In: Kaplan E, Brookmeyer R, editors. Quantitative Evaluation of HIV Prevention Programs. New Haven, Yale University Press; 2001.
32. Blower SM, McLean AR. Prophylactic vaccines, risk behavior change and the probability of eradicating HIV in San Francisco. Science 1994; 265:1451-1454.
33. Gazzard B, Moyle G. 1998 Revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee. Lancet 1998; 352:314-316.